Fact-checked by Grok 2 weeks ago

Incremental cost-effectiveness ratio

The incremental cost-effectiveness ratio (ICER) is a fundamental metric in that evaluates the relative efficiency of medical interventions by dividing the difference in costs between two alternatives by the difference in their health outcomes, yielding the additional cost required per unit of incremental benefit, often measured in quality-adjusted life years (QALYs). This ratio facilitates comparisons across treatments, enabling policymakers and payers to determine whether the added expense of a new justifies its marginal gains, with lower ICER values indicating greater value for money. ICERs are calculated as ICER = \frac{C_1 - C_0}{E_1 - E_0}, where C_1 and C_0 denote the costs of the new and interventions, respectively, and E_1 and E_0 represent their corresponding levels, typically derived from randomized trials or modeling studies that account for both and quality-of-life impacts. In practice, agencies such as the UK's National Institute for Health and Care Excellence () apply ICER thresholds—commonly £20,000 to £30,000 per QALY—to guide reimbursement decisions, prioritizing interventions below these benchmarks while scrutinizing those exceeding them for exceptional circumstances like . Despite its ubiquity, the ICER has drawn criticism for statistical vulnerabilities, particularly in generating unreliable confidence intervals when incremental effectiveness is small relative to its variability, potentially leading to misguided policy conclusions, and for prompting debates over alternatives like net monetary benefit that avoid ratio-specific paradoxes.

Definition and Formula

Core Definition and Interpretation


The (ICER) quantifies the additional per unit of additional benefit when comparing two , typically a new treatment against a standard or no . It is computed as the ratio of the incremental (\Delta C = C_1 - C_0) to the incremental effectiveness (\Delta E = E_1 - E_0), where subscript 1 denotes the new and 0 the . Effectiveness E is commonly expressed in quality-adjusted life years (QALYs), though other natural units like life years gained or cases averted may be used depending on the context.
Interpretation of the ICER hinges on its position relative to a cost-effectiveness , which represents the maximum willingness-to-pay for an additional unit of benefit, often derived from per capita GDP or healthcare constraints. A positive ICER in the northeast quadrant of the cost-effectiveness plane—indicating higher costs and greater effectiveness—suggests the may be cost-effective if below the ; for instance, the UK's National Institute for Health and Care Excellence () deems interventions with ICERs under £20,000 per QALY generally cost-effective, with higher values up to £30,000 requiring additional justification such as substantial innovation or equity impacts. In the United States, thresholds around $100,000–$150,000 per QALY have been proposed by organizations like the Institute for Clinical and Economic Review (ICER). Interventions in the southeast quadrant (lower costs, higher effectiveness) are dominant and unambiguously preferable, while those in the northwest (higher costs, lower effectiveness) are dominated and typically rejected. The ICER facilitates in resource-limited settings by enabling ordinal ranking of options, though it assumes linear trade-offs and may overlook impacts or considerations unless explicitly incorporated. Negative ICERs arise when incremental costs and effectiveness move oppositely, signaling either extended dominance (reject if more effective but cheaper alternative exists) or challenges in interpretation requiring sensitivity analyses. Thresholds are not universal; they reflect jurisdictional values, with lower thresholds in systems like the UK's emphasizing fiscal prudence.

Mathematical Formulation


The incremental cost-effectiveness ratio (ICER) is mathematically expressed as the difference in costs between two alternatives divided by the difference in their effectiveness measures. This standard formulation, ICER = \frac{C_1 - C_0}{E_1 - E_0}, quantifies the additional cost required per unit increase in effectiveness when comparing a new (subscript 1) against a or (subscript 0). Here, C_1 and C_0 represent the total expected costs, including direct medical expenses, while E_1 and E_0 denote the expected health outcomes, such as quality-adjusted life years (QALYs) or life years gained.
The denominator E_1 - E_0 must be positive for the ICER to yield a finite positive value, assuming the new provides greater ; otherwise, if the intervention dominates (lower and higher ), the ICER is conventionally or interpreted as negative , indicating unequivocal . Costs and are typically derived from decision-analytic models, clinical trials, or observational data, discounted to using rates like 3% annually to reflect time preferences. Variations in notation may appear, but the core ratio remains consistent across applications.

Historical Development

Origins in Health Economics

The application of (CEA) to , from which the incremental cost-effectiveness ratio (ICER) emerged, began in the mid-1960s amid growing concerns over escalating medical costs and in programs like . Clarence Klarman, often credited as a foundational figure in , published early CEAs evaluating interventions for chronic conditions, such as renal and , by comparing their costs to gains in relative to no or alternative care. These analyses implicitly employed incremental reasoning, computing additional expenditures against additional health outcomes to assess value for public investment decisions. By the , as CEA proliferated in response to needs for evaluating technologies like and pharmaceuticals, economists distinguished incremental metrics from average cost-effectiveness ratios to avoid distortions when baselines differed. The ICER, expressed as the difference in costs divided by the difference in effectiveness between comparators, formalized this by focusing on marginal costs and benefits, enabling identification of dominated strategies where one option provided superior outcomes at lower or equivalent cost. This shift addressed causal realities in interventions, where absolute averages often ignored costs and efficiencies.01764-2/fulltext) The ICER's methodological consolidation occurred in the , coinciding with refinements in outcome measurement, such as the development of quality-adjusted life years (QALYs) by Alan Williams and colleagues around 1976–1985, which allowed ICERs to quantify trade-offs in both survival and health-related quality. Early adopters, including U.S. government panels and academic works by Michael Drummond, emphasized ICERs for their transparency in decision-making, though initial applications remained rudimentary, often relying on life-years saved without or testing. This evolution reflected empirical pressures from constrained budgets, prioritizing interventions with favorable incremental ratios to maximize gains.

Institutional Adoption and Evolution

The in the formalized the use of the incremental cost-effectiveness ratio (ICER) upon its establishment in 1999, incorporating it into health technology appraisals to guide funding decisions, with an initial threshold range of £20,000 to £30,000 per gained. This adoption marked a pivotal institutional shift, drawing on prior academic developments in cost-utility analysis but applying ICER systematically to ration scarce resources amid fixed budgets, prioritizing interventions below the threshold while allowing flexibility for higher values in cases of substantial health gains. 's framework evolved through refinements, such as explicit guidance on probabilistic by 2013 and adjustments to end-of-life criteria permitting ICERs up to £30,000/QALY or higher for severe conditions. Australia's Pharmaceutical Benefits Advisory Committee (PBAC) integrated ICER into its evaluations of pharmaceutical subsidies starting in the early , with formal guidelines emphasizing cost-effectiveness relative to comparators, though without a fixed monetary threshold; decisions hinge on whether the ICER represents value for money, often informed by QALY increments and budget impact. Canada's CADTH (Canadian Agency for Drugs and Technologies in Health), evolving from the Common Drug Review launched in 2001, adopted ICER as a core metric in its 2006 guidelines for economic evaluations, recommending reimbursement only for therapies demonstrating favorable ICERs against clinical benefits, with re-assessments over time to address emerging evidence. These agencies' approaches reflect causal priorities in , where ICER quantifies trade-offs but is tempered by non-economic factors like and incentives. In the United States, lacking a centralized public HTA body, the Institute for Clinical and Economic Review (ICER)—founded in 2007—emerged as a private nonprofit conducting ICER-based assessments, producing initial reports in 2008 and scaling to 12 annually by 2018 before stabilizing. ICER's methodology mirrors international standards, such as NICE's QALY focus, but incorporates U.S.-specific elements like insurer perspectives and has iteratively updated its framework, including 2023 revisions benchmarked against global HTA practices to enhance equity considerations without formal thresholds. Globally, ICER adoption proliferated through the 2000s in agencies like those in and , evolving from ad hoc economic reviews to standardized protocols amid critiques of threshold arbitrariness—often derived from gross domestic product per capita multiples rather than direct empirical willingness-to-pay data—yet empirically linked to coverage rates, with interventions below thresholds adopted at higher frequencies. This institutional trajectory underscores ICER's role in constraining expenditures while fostering evidence-based prioritization, though variations persist due to national fiscal contexts and political influences on threshold enforcement.

Calculation and Methodology

Incremental Cost Estimation

Incremental costs in refer to the difference in total expected costs between a new and its , denoted as C_1 - C_0, where C_1 is the cost of the intervention and C_0 is the cost of the alternative. This differential captures the net attributable to adopting the intervention, essential for computing the incremental cost-effectiveness ratio (ICER). requires identifying all relevant resource uses, valuing them at appropriate unit prices, and adjusting for time preferences and to ensure comparability over the analysis horizon. The choice of analytical perspective determines the scope of costs included, influencing the magnitude of the incremental estimate. From a healthcare payer perspective, such as that recommended by the UK's National Institute for Health and Care Excellence (NICE), only direct costs borne by the (NHS) and Personal Social Services (PSS)—including staff time, pharmaceuticals, hospital stays, and infrastructure—are considered, explicitly excluding losses. In contrast, a societal perspective, as advocated in U.S. guidelines, incorporates broader opportunity costs, such as patient travel, caregiver time, and indirect impacts, using reimbursements or cost-adjusted charges as proxies where direct is infeasible. Payer perspectives predominate in policy-driven assessments to align with budgetary constraints, though they may understate true societal burdens. Cost components are typically categorized into direct medical (e.g., via healthcare resource groups or diagnosis-related groups, outpatient visits, diagnostics), direct non-medical (e.g., patient transportation), and indirect (e.g., ), with varying by . Unit costs are derived from sources like national reimbursement schedules, drug pricing databases (e.g., NHS Electronic Market Information Tool for pharmaceuticals), or average institutional charges adjusted by cost-to-charge ratios. Resource utilization data stem from randomized controlled trials (via patient diaries or claims extraction), administrative databases, or decision-analytic models extrapolating trial results. Micro-costing, which tallies individual s multiplied by unit prices, offers precision for novel interventions but demands extensive data; gross-costing applies average episode costs for efficiency in routine settings. Future costs are discounted at rates like 3.5% annually ( standard) or 3% (U.S. recommendations) to reflect time value, applied consistently to both numerator streams in the ICER to avoid bias; non-discounted costs may be reported supplementally for short horizons. Inflation adjustments use indices such as the for medical care or Personal Health Care Expenditure deflators to express values in base-year prices. Uncertainty in estimates arises from parameter variability (e.g., fluctuations) and structural assumptions (e.g., generalizability across settings), addressed via probabilistic or , such as varying discount rates or excluding research-specific overheads like enrollment. Challenges include data gaps in long-term utilization, jurisdictional price variations, and the exclusion of intangible costs, potentially leading to incomplete incremental assessments that overlook transition or implementation expenses.

Incremental Effectiveness Measurement

Incremental effectiveness in cost-effectiveness analysis refers to the difference in health outcomes, denoted as E_1 - E_0, between two interventions, where E_1 represents the expected effectiveness of the new or comparator intervention and E_0 that of the baseline or standard care. This difference captures the additional benefit, such as improved survival or , attributable to adopting one strategy over another. The recommended measure for effectiveness in most health economic evaluations is the (QALY), which integrates both the quantity and gained. A QALY represents one year of life in perfect ; partial health states are weighted on a scale from 0 (equivalent to death) to 1 (full ), derived from preference-based instruments like the or SF-6D. Incremental QALYs are calculated by summing the product of time spent in each and its corresponding utility weight for the intervention minus the same for the comparator, often discounted at rates like 3-5% to reflect . inputs typically come from randomized controlled trials, meta-analyses of clinical effectiveness, or decision-analytic models such as Markov chains that extrapolate short-term trial results to lifetime horizons. Alternative measures include unadjusted life years gained, which quantify only survival extension without quality adjustments, and disability-adjusted life years (DALYs) averted, which sum years of life lost due to premature mortality and years lived with using global disability weights. QALYs are preferred in cost-effectiveness assessments by bodies like the U.S. Service Task Force for their ability to compare diverse interventions on a common metric, though DALYs are more common in global burden-of-disease studies focused on population-level impacts. The choice of measure can influence results; for instance, QALY gains often exceed DALYs averted in preventive interventions due to differences in weighting methodologies, with QALYs relying on preferences and DALYs on expert-derived disability weights. Utility weights for QALY calculation are elicited via methods like or standard gamble, reflecting societal or patient valuations, but variations across instruments and populations can introduce uncertainty, necessitating sensitivity analyses in health technology assessments.

Uncertainty Analysis and Reporting

Uncertainty in incremental cost-effectiveness ratio (ICER) analyses arises primarily from parameter variability, such as estimates of costs and outcomes derived from clinical trials or observational data, as well as from model structural assumptions and beyond observed periods. uncertainty is quantified by assigning probability distributions to input , reflecting their sampling variability, while structural uncertainty stems from choices in model design that may not fully capture real-world complexities. To address these, analyses employ sensitivity analyses to test the robustness of ICER results to variations in inputs. Deterministic sensitivity analysis (DSA) involves varying one or more parameters systematically, such as through one-way (univariate) or multi-way scenarios, to identify influential inputs on the ICER, but it does not fully propagate joint uncertainties across parameters. Probabilistic sensitivity analysis (PSA), recommended by guidelines from bodies like the UK's National Institute for Health and Care Excellence (), uses simulations to repeatedly sample from joint probability distributions of all uncertain parameters, generating a distribution of possible ICER values. In PSA, parameters like transition probabilities in Markov models follow distributions for proportions, gamma for costs, and log-normal for effects, enabling estimation of the probability that an intervention is cost-effective at a given willingness-to-pay threshold.32408-7/fulltext) Reporting of uncertainty emphasizes transparency to inform , including point estimates of the mean ICER alongside measures of dispersion, such as 95% credible intervals from PSA iterations (typically 1,000–10,000 simulations). Visual tools include cost-effectiveness planes, plotting simulated incremental cost-effectiveness pairs to show scatter around the point estimate, and cost-effectiveness acceptability curves (CEACs), which graph the probability of cost-effectiveness against varying thresholds. Cost-effectiveness acceptability frontiers (CEAFs) extend this by identifying the intervention with the highest probability across thresholds, while (EVPI) quantifies potential value from resolving uncertainties, calculated as the difference between expected costs under current information and perfect certainty. Guidelines stress reporting both deterministic and probabilistic results, with PSA preferred for its comprehensive uncertainty propagation, though limitations like correlated parameters or unmodeled heterogeneity must be acknowledged.

Applications in Practice

Role in Health Technology Assessment

The incremental cost-effectiveness ratio (ICER) serves as a core quantitative tool in (HTA), enabling agencies to evaluate whether the additional costs of a new intervention are justified by its incremental health benefits compared to standard care or alternatives. HTA processes typically involve reviewing manufacturer-submitted economic models that estimate ICERs, often expressed as cost per (QALY) gained, to inform recommendations on public reimbursement, formulary inclusion, or clinical guideline adoption. By standardizing comparisons across technologies, ICER facilitates prioritization of interventions that maximize health outcomes within constrained budgets, though it is integrated with qualitative factors such as clinical efficacy and safety data. In jurisdictions with formalized HTA, ICERs are benchmarked against willingness-to-pay thresholds derived from GDP or empirical estimates; for example, the UK's National for Health and Care Excellence () deems interventions cost-effective if their ICER falls below £20,000–£30,000 per QALY, with higher values potentially approved only if substantial additional benefits (e.g., or broader societal gains) are demonstrated. Similarly, Canada's CADTH assesses ICERs in its pan-Canadian Pharmaceutical Review, revising sponsor-submitted estimates upward in cases of overly optimistic assumptions, which often leads to price reduction recommendations when ICERs exceed implicit thresholds around CAD$50,000 per QALY. These thresholds guide binary decisions—recommend, recommend with restrictions, or do not recommend—but HTA bodies conduct sensitivity analyses to test ICER robustness against parameter variations, such as discount rates or long-term extrapolations. ICER's role extends to pricing negotiations and disinvestment decisions, where high ICERs signal inefficient resource use and prompt calls for manufacturer discounts to achieve favorable ratios. For instance, incremental analysis prevents adoption of dominated technologies (those more costly and less effective) and supports in single-payer systems. However, reliance on ICER assumes accurate modeling of real-world outcomes, and agencies like and CADTH supplement it with budget impact assessments to address short-term fiscal constraints not captured in lifetime ICER horizons. While ICER promotes transparency, its application varies by institutional mandates, with some HTA entities weighting non-economic factors more heavily in final rulings.

Use in Pharmaceutical and Intervention Decisions

The incremental cost-effectiveness ratio (ICER) serves as a key metric for payers, agencies, and policymakers in evaluating whether new pharmaceuticals or warrant reimbursement or adoption, by quantifying the additional cost required to achieve an extra unit of health benefit, such as a (QALY). Agencies compare the ICER of a proposed against comparators like standard care or ; values below predefined or implicit thresholds indicate sufficient value to justify , influencing formulary inclusions, pricing negotiations, and coverage determinations. In the , the integrates ICER into technology appraisals for pharmaceuticals, recommending funding through the if the ratio falls below £20,000 per QALY, while ratios between £20,000 and £30,000 per QALY may receive approval contingent on evidence of wider societal benefits or innovation, and those exceeding £30,000 per QALY face rejection absent compelling justifications like substantial uncaptured health gains. This approach has led to rejections of high-ICER drugs, such as certain treatments, prompting manufacturers to offer discounts to align with the threshold. Australia's Pharmaceutical Benefits Advisory Committee (PBAC) employs ICER assessments in submissions for the , where ratios under approximately AUD 50,000 per QALY are typically viewed as favorable for subsidization, though the committee lacks a formal and weighs clinical need alongside economic . In Canada, the Canadian Agency for Drugs and Technologies in Health (CADTH) reviews ICERs to advise on public drug plans, prioritizing technologies demonstrating acceptable incremental value without a fixed monetary cutoff, often emphasizing budgetary impact and equity. In the United States, absent a national threshold, the metric guides private insurer formularies and assessments by bodies like for Clinical and Economic Review, which benchmarks ICERs against $100,000–$150,000 per QALY to recommend coverage tiers or price concessions for pharmaceuticals. For non-pharmaceutical interventions, ICER similarly informs prioritization; analyses of surgical procedures in resource-limited settings, for example, rank options by ICER relative to per capita to identify high-value operations like or . Vaccination programs, including those for , rely on ICER to balance deployment costs against reductions in morbidity and mortality, supporting decisions on routine schedules where ratios indicate net societal benefit. Uncertainty in ICERs is routinely addressed through probabilistic sensitivity analyses, enabling decision-makers to gauge robustness across parameter variations.

International Variations

The application of the incremental cost-effectiveness ratio (ICER) in (HTA) exhibits substantial international variation, primarily in the establishment and stringency of cost-effectiveness thresholds, the choice of outcome measures (e.g., quality-adjusted life years [QALYs] versus disability-adjusted life years [DALYs]), and the integration of ICER with other decision criteria such as clinical benefit, budget impact, and equity considerations. High-income countries often reference ICER against implicit or explicit willingness-to-pay thresholds calibrated to per capita (GDP), while low- and middle-income countries (LMICs) more frequently adopt (WHO) guidelines suggesting interventions are cost-effective if the ICER falls below 1–3 times GDP . However, explicit thresholds are absent in many jurisdictions, where ICER informs but does not solely determine reimbursement decisions. In the , the National Institute for Health and Care Excellence () employs a of £20,000–£30,000 per QALY gained for most interventions, with approvals above £30,000 possible for technologies demonstrating substantial innovation, end-of-life benefits, or ultra-rare disease applications, as reaffirmed in 's 2022 methods update. By contrast, Australia's Pharmaceutical Benefits Advisory Committee (PBAC) lacks a formal monetary , instead evaluating ICERs holistically alongside clinical , , and societal burden, though submissions with ICERs exceeding approximately AUD 50,000–70,000 per QALY face heightened scrutiny, per analyses of historical decisions through 2020. Canada's Common Drug Review, managed by the Canadian Agency for Drugs and Technologies in Health (CADTH), similarly forgoes explicit , weighing ICERs against factors like disease severity and alignment with provincial formularies, resulting in approvals for higher ICERs in areas of unmet need as of 2023 guidelines. Germany's Institute for Quality and Efficiency in Health Care (IQWiG) diverges markedly by eschewing fixed ICER thresholds altogether, prioritizing demonstrable added therapeutic benefit over comparators via an efficiency frontier approach; cost-effectiveness is assessed only for technologies with proven superiority, often rejecting those reliant solely on probabilistic modeling without clinical added value, as outlined in IQWiG's 2016–2023 assessment protocols. In the , the Zorginstituut Nederland applies tiered guidance: ICERs below €20,000 per QALY typically warrant recommendation, €20,000–€50,000 require negotiation, and those exceeding €80,000 are rarely approved absent exceptional circumstances, reflecting a 2015–2022 framework balancing fiscal constraints with innovation. Among LMICs, Thailand's Health Intervention and Technology Assessment Program explicitly sets thresholds at 1–3 times GDP per capita (approximately THB 100,000–300,000 per QALY as of 2015 data), facilitating broader access to interventions in resource-limited settings. These differences stem from varying healthcare funding models, institutional mandates, and empirical estimates of societal willingness-to-pay; for instance, supply-side thresholds derived from costs (e.g., 0.5–1 times GDP in high-income settings) contrast with demand-side willingness-to-pay surveys, leading to ongoing debates over in cross-border HTA collaborations like the European Network for Health Technology Assessment (EUnetHTA) as of 2023. In Central and Eastern European countries, eight nations (, Czechia, , , , , , ) maintain official ICER thresholds tied to GDP multiples, while others rely on informal benchmarks, highlighting transitional adoption patterns per 2022 analyses. Absent universal standards, such variations can yield divergent outcomes for the same across borders, complicating global pharmaceutical and .

Cost-Effectiveness Thresholds

Basis for Threshold Selection

Cost-effectiveness thresholds in represent the maximum incremental cost-effectiveness ratio (ICER) considered acceptable for adopting an intervention, typically framed as cost per (QALY) gained. Their selection is theoretically rooted in economic principles of , where the threshold approximates the health benefits forgone by reallocating marginal healthcare expenditures to less efficient uses. This supply-side approach prioritizes empirical estimation of the healthcare sector's productivity frontier, using econometric models to quantify health losses from inefficient spending, rather than demand-side willingness-to-pay (WTP) surveys which may reflect individual preferences disconnected from public budget constraints. In practice, thresholds are derived from analyses of historical reimbursement decisions, cost-frontier efficiency studies, and simulations of budget impacts on displaced interventions. For instance, in the United Kingdom, the National Institute for Health and Care Excellence (NICE) employs a range of £20,000–£30,000 per QALY, informed by econometric evaluations of National Health Service (NHS) resource allocation, which estimate the marginal productivity of NHS expenditures at approximately £12,000–£37,000 per QALY depending on model specifications and time horizons. These estimates arise from sector-level data on adopted technologies and their implied displacement effects, highlighting that thresholds below £20,000 risk underfunding efficient care while exceeding £30,000 may crowd out higher-value alternatives. NICE's range, established since 1999, balances empirical evidence with policy considerations but has faced scrutiny for not fully incorporating updated opportunity cost data suggesting a lower bound closer to £15,000–£20,000. Internationally, the (WHO) has recommended thresholds of 1–3 times () for low- and middle-income countries since 2001, intended as a for affordability rather than a direct measure of local health opportunity costs. However, empirical studies across countries indicate these GDP multiples often overestimate viable thresholds, with supply-side estimates typically falling below 1 times GDP to align with actual efficiency frontiers and avoid excessive opportunity costs in resource-constrained systems. In the United States, lacking a centralized threshold, organizations like the Institute for Clinical and Economic Review (ICER) reference ranges such as $50,000–$150,000 per QALY, drawing from historical WTP benchmarks and sector analyses estimating opportunity costs around $50,000–$70,000 based on and private payer data. Selection challenges persist due to data limitations, such as incomplete adoption records and modeling assumptions, underscoring the need for ongoing empirical validation over arbitrary conventions.

Empirical Justifications and Challenges

Empirical justifications for cost-effectiveness thresholds in incremental cost-effectiveness ratio (ICER) analyses emphasize supply-side estimates derived from the costs of marginal healthcare expenditures. These thresholds reflect the benefits foregone when resources are allocated to less productive interventions, estimated through econometric models linking spending variations to outcomes like mortality or quality-adjusted life years (QALYs). For the English , Claxton et al. (2015) calculated a central of £18,317 per QALY (in 2008 prices) based on instrumental variable analyses of program budgeting data and outcomes from 2003–2010, suggesting that expenditures above this level displace more effective care elsewhere in the system. Similar supply-side approaches in other contexts, such as (€22,000–€25,000 per QALY) and (approximately $28,000 per QALY), use analogous methods to quantify resource constraints under fixed budgets. Revealed preference methods offer additional empirical grounding by inferring thresholds from observable behaviors, such as wage risks in hazardous occupations or judicial awards for statistical life years. In the United States, analyses of risky job premiums and legal precedents have produced estimates ranging from $38,250 ± $11,500 per QALY (occupational risks) to $50,800 ± $6,520 per QALY (legal values), averaging around one times GDP . These approaches aim to capture societal without relying on stated preferences, which are prone to hypothetical bias. Challenges in these estimations undermine their reliability for . Supply-side models face issues, where unobserved factors confound spending-outcome links, and limitations—such as aggregated mortality metrics without comprehensive QALY measures—restrict ; for instance, English analyses rely on proxies due to absent quality-of-life at the program level. estimates vary widely by method and context, with occupational often outdated and legal values influenced by jurisdictional inconsistencies, leading to a lack of (e.g., U.S. figures cluster below $100,000 per QALY but conflict with higher benchmarks). Many adopted thresholds, including WHO's 1–3 times GDP per capita guideline used in low- and middle-income countries, derive from multiples rather than localized , potentially misaligning with actual opportunity costs and fostering inefficient . Uncertainty analyses in threshold derivations, such as those incorporating elasticity of outcomes to spending, highlight broad confidence intervals that question their use as fixed decision rules.

Policy Debates and Adjustments

In the United Kingdom, the National Institute for Health and Care Excellence (NICE) has maintained a cost-effectiveness threshold range of £20,000 to £30,000 per quality-adjusted life year (QALY) gained since its formal adoption around 1999, without routine inflation adjustments despite rising healthcare costs and opportunity costs estimated at approximately £15,000 per QALY based on empirical analyses of NHS resource displacement. This stasis has fueled debates, with some health economists arguing for a downward revision to better align with marginal productivity estimates derived from sector-level data, while pharmaceutical industry representatives, such as the Association of the British Pharmaceutical Industry (ABPI), advocate for an upward adjustment to £40,000–£50,000 per QALY, indexed to inflation, to accommodate innovative therapies and prevent rationing amid stagnant NHS budgets. Recent policy pressures in 2025 have intensified these discussions, with reports indicating the government is considering a 25% increase to the —potentially raising the to £25,000–£37,500 per QALY—to address access barriers for high-value drugs, influenced partly by international trade negotiations and criticisms of overly restrictive evaluations hindering patient outcomes. itself has implemented methodological adjustments, such as replacing end-of-life modifiers with a broader severity framework in 2022, to refine application without altering the base , aiming to incorporate considerations while preserving fiscal discipline. Critics, including health economists, warn that politically driven upward shifts risk undermining evidence-based , as thresholds should reflect verifiable opportunity costs rather than or short-term political expediency. In the United States, where no federal threshold exists, for Clinical and Economic Review (ICER) employs a $100,000–$150,000 per QALY benchmark for its assessments, sparking debates over its informal influence on private payers and policymakers amid concerns that lower implicit thresholds in negotiations could stifle pharmaceutical innovation. Proponents argue this range approximates willingness-to-pay estimates from studies, but detractors highlight affordability constraints, with surveys of researchers revealing tensions between cost-effectiveness and budget impacts, particularly for high-cost specialties. Policy adjustments have included ICER's 2019 reaffirmation of the range despite calls for integration of non-QALY metrics like unmet need, reflecting ongoing contention over whether thresholds should prioritize aggregate efficiency or incorporate broader social values. Internationally, the recommends thresholds of 1–3 times (GDP) per capita for low- and middle-income countries, but high-income nations debate adaptations; for instance, Australia's Pharmaceutical Benefits Advisory Committee applies a flexible threshold around A$50,000 per QALY with upward adjustments for severity, prompting criticisms that such variability introduces subjectivity and potential bias favoring certain interventions. These debates underscore a core tension: while thresholds facilitate transparent decisions, adjustments often arise from empirical revisions to estimates or political responses to access inequities, yet fixed or arbitrary changes risk distorting incentives for cost-effective innovation.

Advantages and Empirical Support

Efficiency in Resource Allocation

The incremental cost-effectiveness ratio (ICER) enhances efficiency in by enabling comparisons of the marginal costs and health outcomes across interventions, allowing decision-makers to prioritize those delivering the greatest additional per unit cost expended. Formally, ICER is calculated as the difference in costs divided by the difference in effectiveness between two alternatives, typically expressed as ICER = \frac{C_1 - C_0}{E_1 - E_0}, where C_1 and C_0 denote costs of the new and comparator interventions, and E_1 and E_0 their respective effectiveness measures, such as quality-adjusted life years (QALYs). This metric supports the identification of interventions that expand the health production frontier under budgetary constraints, displacing lower-value options to optimize overall system output. In practice, ICER facilitates at meso and macro levels by informing choices that maximize gains subject to fixed resources, as decision-makers select interventions with ICERs below an threshold, thereby minimizing waste and enhancing net societal . Theoretical models demonstrate that ranking and funding by ascending ICER up to the budget limit achieves the , where no reallocation could yield more without additional funds. Applications in systems, such as prioritizing new services in benefit packages, underscore ICER's role in sustaining fiscal viability while targeting high-impact uses of funds. While direct causal empirical evidence linking ICER adoption to measurable efficiency gains remains limited, its use in structured assessments consistently reveals opportunity costs of adopted programs, guiding reallocation toward higher-return investments and reducing inefficiencies from decisions. For instance, analyses incorporating ICER thresholds have supported geographic and programmatic shifts that align expenditures with evidence-based value, though accurate estimation requires robust data to avoid distortions from biased .

Facilitation of Transparent Decision-Making

The incremental cost-effectiveness ratio (ICER) promotes transparency in healthcare decision-making by offering a standardized, quantifiable metric that explicitly quantifies the additional cost required to achieve an extra unit of health benefit, such as a (QALY), thereby reducing reliance on opaque or subjective judgments. In (HTA) processes, this enables agencies to publicly disclose the trade-offs between costs and outcomes, fostering accountability as stakeholders can scrutinize whether decisions align with evidence-based criteria rather than ad hoc considerations. For example, bodies like the UK's National Institute for Health and Care Excellence (NICE) routinely publish ICER estimates alongside detailed appraisals, allowing external review of how economic evidence influences recommendations for funding new interventions. Empirical analyses of decisions from 1999 to 2013 demonstrate that ICER values strongly predict approval rates, with technologies yielding ICERs under £20,000 per QALY approved in over 90% of cases, while those exceeding £30,000 faced rejection in about 60%, illustrating a systematic application that minimizes arbitrary outcomes. This underscores ICER's role in making explicit, as deviations from thresholds—due to factors like or —are justified in public documents, enhancing trust in the process. Similarly, , the Institute for Clinical and Economic (ICER) generates transparent reports integrating ICERs with clinical evidence, informing payers and policymakers on value without formal mandates, which has spurred public debates on pricing and access since its inception in 2004. By facilitating comparisons across interventions and jurisdictions, ICER supports cross-border learning and policy scrutiny; for instance, HTA collaborations reference ICER thresholds to , as seen in alignments between and entities like Canada's CADTH, where shared methodologies promote verifiable consistency in evaluations. This evidentiary foundation counters criticisms of black-box in pre-ICER eras, where funding choices often lacked disclosed metrics, thereby empowering patients, clinicians, and taxpayers to engage with—and challenge—allocative priorities grounded in data.

Criticisms and Limitations

Technical and Methodological Shortcomings

The incremental cost-effectiveness ratio (ICER) is inherently sensitive to small variations in its numerator (incremental costs) or denominator (incremental effectiveness, often measured in quality-adjusted life years or QALYs), which can produce unstable or misleading estimates, particularly when the incremental effectiveness is minimal, resulting in disproportionately high ICER values. Negative ICERs further complicate interpretation, as they may indicate either a dominant (cheaper and more effective) or an extendedly dominated one (more expensive and less effective), without clear guidance for across studies. This ratio-based structure precludes straightforward intervals, as each ICER value corresponds to paired points on cost-effectiveness planes, amplifying uncertainty in probabilistic sensitivity analyses. Heterogeneity across ICER estimates arises from inconsistent methodological choices, including varying populations (e.g., differing patient eligibility criteria in interventions), comparators (e.g., ambiguous "standard care" definitions by jurisdiction), and outcome measures (e.g., multiple utility elicitation methods like variants yielding divergent QALYs). Time horizons often mismatch intervention durations, with short-term trial data extrapolated to lifetimes via models prone to structural uncertainties, such as unverified disease progression assumptions, especially underestimating benefits in rare or chronic conditions. Discounting practices exacerbate this, as rates differ by guideline (e.g., 3.5% in versus 1.5% in CADTH for health effects), differentially impacting long-term interventions and rendering cross-study comparisons unreliable. The reliance on QALYs introduces further technical flaws, as no standardized utility metric exists; generic instruments like EQ-5D-3L often fail to capture disease-specific quality-of-life dimensions, while ad-hoc literature-sourced values lack empirical validation and introduce non-refutable assumptions. Perspectives vary (e.g., payer-focused excluding societal productivity gains versus broader societal views), leading to ICER divergence; for instance, omitting future price dynamics or non-healthcare costs in lifetime models distorts realism. Although probabilistic addresses parameter uncertainty, it cannot quantify structural or scenario-based uncertainties, such as alternative paths, limiting the robustness of ICER-derived decisions.

Ethical and Equity Issues

The reliance on ICER for prioritizing healthcare interventions raises ethical concerns about the of human , as it translates differential life expectancies and quality-of-life assessments into monetary thresholds that may systematically undervalue treatments for vulnerable populations. For instance, patients with chronic disabilities or advanced age often yield fewer QALYs due to states, leading ICERs to deem such interventions inefficient despite potential benefits, thereby embedding utilitarian trade-offs that prioritize gains over personalized . This approach has been critiqued for implicitly access based on probabilistic averages rather than clinical need, exacerbating moral hazards in systems with fixed budgets where denying high-ICER therapies shifts opportunity costs onto patients without recourse. Equity issues stem from ICER's failure to incorporate distributional impacts, treating all QALYs as equivalently valuable regardless of the recipient's socioeconomic position, disease burden, or systemic disadvantages, which can widen disparities in health outcomes. Empirical reviews indicate that unadjusted ICER models disproportionately favor interventions benefiting younger, healthier, or higher-income groups, as evidenced by lower adoption rates for therapies targeting low-income or minority populations in threshold-based appraisals. For example, cost-effectiveness thresholds around $50,000–$150,000 per QALY, as applied by U.S. payers or UK's NICE, often exclude rare disease treatments with sparse trial data, disproportionately affecting underserved communities where such conditions prevail. Proposals to address these gaps, such as equity-adjusted ICERs that weight QALYs higher for severe illnesses or groups, introduce subjective parameters that risk undermining the method's empirical , as weights derived from surveys or ethical deliberations vary widely and may reflect societal preferences biased toward redistribution over . Critics contend this modifies causal toward normative goals, potentially distorting incentives for in high-burden areas, while shows standard ICERs correlate with sustained system savings but at the cost of heterogeneous access, as in NICE's 2002–2020 appraisals where equity modifiers were applied to about 10% of end-of-life cases without formalized criteria. Such inconsistencies highlight tensions between consequentialist and deontological fairness, with academic for weighting often presuming egalitarian priors that overlook first-principles incentives for broad access.

Effects on Innovation and Patient Access

The reliance on ICER thresholds by payers and policymakers to determine reimbursement eligibility has been criticized for limiting patient access to innovative therapies that exceed cost-effectiveness benchmarks, particularly high-cost treatments for rare or severe conditions. Drugs assigned unfavorable ICER values, such as those surpassing $150,000 per quality-adjusted life year (QALY), often face coverage denials or stringent utilization management, resulting in out-of-pocket burdens or treatment abandonment for affected patients. For example, assessments deeming certain orphan drugs as low-value have contributed to restricted formulary placement in U.S. states adopting ICER-influenced pharmacy and therapeutics decisions, reducing availability of ulcerative colitis therapies despite clinical benefits. Industry analyses attribute these barriers to ICER's emphasis on short-term budget impacts over individual patient needs, potentially exacerbating inequities for those with unmet medical demands. On innovation, ICER-driven price negotiations and thresholds exert downward pressure on expected revenues for marginal or high-ICER innovations, theoretically disincentivizing R&D in pharmaceuticals. Empirical modeling links revenue reductions from such controls—common in assessments—to diminished innovation outputs; specifically, a 10% decline in anticipated U.S. drug revenues correlates with up to a 15% drop in new treatment development, as firms reallocate resources to more profitable, lower-risk projects. This dynamic efficiency concern is amplified for orphan drugs, where ICER's payer-perspective undervalues broader societal benefits like productivity gains, potentially slowing progress in ultra-rare disease pipelines. While no large-scale causal studies directly attribute R&D stagnation to ICER specifically, cross-national evidence from threshold-adopting systems like the 's suggests launch delays and selective shifts, with critics noting persistent underfunding for therapies failing static cost-effectiveness tests. Proponents of ICER thresholds counter that they foster efficient , channeling innovation toward with stronger evidence of net benefit, but empirical critiques highlight methodological flaws—like neglect of dynamic R&D spillovers—that may systematically undervalue transformative drugs, risking a on upstream . In practice, this has manifested in payer behaviors prioritizing low-ICER alternatives, as seen in cases where stable patients on high-ICER regimens face step mandates or prior authorizations, further constraining access. Such limitations underscore the tension between cost containment and sustaining a robust pipeline of medical advances.

Alternatives and Extensions

The net monetary benefit (NMB) is a used in to evaluate by converting health outcomes into monetary equivalents relative to a willingness-to-pay (WTP) threshold, typically expressed as dollars per (QALY). It is calculated as NMB = λ × ΔE - ΔC, where λ represents the WTP threshold (e.g., $50,000–$150,000 per QALY in various jurisdictions), ΔE is the incremental effectiveness (such as QALYs gained), and ΔC is the incremental cost. A positive NMB indicates that the intervention generates exceeding its costs at the specified threshold, equivalent to an incremental cost-effectiveness ratio (ICER) below λ, since NMB > 0 ΔC / ΔE < λ. This approach addresses limitations of ICER, such as undefined ratios when ΔE approaches zero or challenges in aggregating probabilistic results, by enabling direct arithmetic comparisons and on means rather than ratios. Introduced by Stinnett and Mullahy in , NMB facilitates threshold-independent reporting by allowing analysts to compute benefits for multiple λ values, producing NMB frontiers that visualize cost-effectiveness across WTP ranges without relying on ratio planes. For instance, in probabilistic sensitivity analyses, NMB supports cost-effectiveness acceptability curves by ranking strategies based on expected NMB, which integrates costs, outcomes, and more straightforwardly than ICER ellipses. Empirical applications, such as evaluations of strategies, have used NMB to quantify population-level benefits, showing positive values for interventions like varicella vaccination when societal costs are included, though results vary with assumptions (e.g., $ per QALY yielding higher NMB than lower values). Related metrics include net health benefit (NHB), defined as NHB = ΔE - (ΔC / λ), which scales outcomes to units rather than monetizing them fully and is mathematically equivalent to NMB divided by λ. NHB is particularly useful in settings prioritizing maximization over monetary valuation, such as when budget constraints imply an λ derived from system-wide data (e.g., UK's reference case at £20,000–£30,000 per QALY). Both NMB and NHB extend ICER by accommodating dominance (where one option is cheaper and more effective) and extended dominance (where a mix outperforms extremes), reducing misclassifications in league tables; studies report NHB/NMB reclassifying up to 10–20% of ICER-based decisions in model-based analyses of therapies. However, their validity hinges on accurate λ estimation, which lacks universal consensus—U.S. thresholds often exceed $100,000 per QALY based on revealed preferences from coverage decisions, while critics argue for evidence-based derivation from displacement costs rather than arbitrary figures. Adoption remains limited in guidelines like those from or ICER, favoring ICER for transparency, though NMB is increasingly applied in U.S. pharmaceutical assessments for its in .

Broader Decision Frameworks

In (HTA), the incremental cost-effectiveness ratio (ICER) serves as a core metric but is often embedded within broader decision frameworks that account for dimensions beyond incremental costs and health outcomes, such as disease severity, equity implications, unmet medical need, and societal impacts. These frameworks recognize that decisions require balancing economic efficiency with ethical, clinical, and policy considerations, particularly when ICER alone may undervalue interventions for rare diseases or . For instance, agencies like the UK's National Institute for Health and Care Excellence (NICE) apply ICER thresholds (typically £20,000–£30,000 per gained) but supplement them with modifiers for exceptional circumstances, including higher thresholds up to £100,000 for end-of-life treatments or ultra-orphan conditions, as outlined in their 2013 methods guide updated in subsequent appraisals. Multi-criteria decision analysis (MCDA) represents a structured extension, evaluating technologies across multiple weighted criteria—including clinical , , economic value (via ICER), patient-reported outcomes, and innovation potential—rather than relying solely on a unidimensional ratio. MCDA frameworks, piloted in HTA processes by bodies such as the Scottish Medicines Consortium and in EUnetHTA collaborations, use scoring and aggregation methods to generate composite value scores, enabling transparent trade-offs; a 2016 review identified over 20 MCDA applications in HTA, often integrating ICER as one criterion weighted at 20–40% depending on stakeholder input. This approach addresses ICER's limitations in capturing non-quantifiable benefits, though it demands rigorous criteria selection to mitigate subjectivity, as evidenced by methodological guidelines from the International Society for and Outcomes Research (ISPOR).01463-0/fulltext) Additional frameworks incorporate affordability and distributional effects, such as generalized risk-adjusted (GRACE), which adjusts ICER for budget constraints and opportunity costs across sectors, or distributional (DCEA), which extends ICER by modeling health gains across socioeconomic groups to prioritize . A 2022 analysis of 17 studies found DCEA frequently used to reveal regressive impacts of standard ICER-based decisions, advocating for progressive weighting in low-income populations. Similarly, five-step appraisal models proposed for Asian HTA contexts evaluate through unmet need, , system-level effects, and perspectives alongside ICER, as applied in evaluations of high-cost therapies. These integrated approaches enhance decision robustness but require empirical validation of weights and thresholds to align with opportunity costs estimated at 1–2 times GDP in many jurisdictions.

Recent Developments

Updates to Guidelines and Practices

In 2023, for Clinical and Economic Review (ICER) finalized updates to its Value Assessment Framework, incorporating new elements such as clinical trial diversity ratings to evaluate representation in studies and scenarios for interventions targeting small patient populations, while maintaining core quantitative methods for calculating incremental cost-effectiveness ratios (ICERs). These revisions aimed to refine evidence synthesis and stakeholder deliberation without altering the fundamental ICER formula or threshold ranges of $100,000 to $150,000 per (QALY). In October 2025, ICER adjusted its annual budget impact threshold for prescription drugs downward from $880 million to $821 million, reflecting updated economic projections to better align with sustainable healthcare spending limits. The National Institute for Health and Care Excellence () in the UK has sustained its ICER threshold range of £20,000 to £30,000 per QALY for most appraisals, with committees required to justify approvals exceeding £20,000 explicitly, amid ongoing analyses questioning potential upward adjustments based on empirical willingness-to-pay data. For highly specialized technologies (), 2025 reforms permit thresholds up to £100,000 per QALY, escalating to £300,000 in exceptional cases involving substantial unmet needs or innovative mechanisms, alongside reduced 1.5% discount rates for costs and health effects in long-term therapies like cell and gene treatments. Canada's CADTH released the fourth edition of its Guidelines for the Economic of Health Technologies in May 2025, emphasizing probabilistic analyses and around ICERs to address parameter uncertainty, while recommending thresholds tied to per-capita GDP multiples without fixed numerical values to enhance flexibility in diverse provincial contexts. The and American College of Cardiology's 2025 statement on cost-value methodology reaffirmed ICER as the primary metric, advocating its integration with clinical guidelines while cautioning against over-reliance on thresholds amid rising U.S. care costs. These evolutions reflect broader trends toward incorporating and equity modifiers, though methodological critiques persist regarding ICER's to input assumptions.

Ongoing Research and Threshold Reassessments

Recent studies have examined the adequacy of fixed ICER thresholds in decentralized healthcare systems like the , highlighting a mismatch between centralized European thresholds and U.S. reimbursement needs, where payers vary widely in their . Researchers argue that rigid thresholds may undervalue innovations in rare diseases or high-burden conditions, prompting calls for flexible, evidence-based ranges informed by empirical payer data rather than arbitrary benchmarks. In 2025, the Institute for Clinical and Economic Review (ICER) reassessed its budget impact threshold for prescription drugs, lowering it from $880 million to $821 million annually to reflect updated economic projections and inflation adjustments, while maintaining cost-effectiveness ranges of $50,000 to $150,000 per quality-adjusted life year (QALY) for primary analyses. This update aligns with ICER's revised reference case, which incorporates sequential exclusion of unrelated future healthcare costs to better capture intervention-specific impacts, addressing prior methodological critiques on over-discounting long-term benefits. Concurrently, analyses of novel drugs approved in 2024 revealed that launch prices often exceed ICER benchmarks, fueling research into dynamic thresholds tied to GDP growth or societal productivity losses. Threshold reassessments in the via the National Institute for Health and Care Excellence () have shown increased acceptance rates for technologies with ICERs above £20,000–£30,000 per QALY, rising from 55% in 2023–2024 to 70% in 2024–2025, particularly for end-of-life or highly specialized treatments where upper limits reach £100,000–£150,000. Empirical studies propose GDP-per-capita multipliers of 0.5–1.5 as more realistic for low- and middle-income contexts, challenging WHO's broader 1–3 times recommendation by emphasizing opportunity costs from displaced interventions. The /American College of Cardiology's 2025 statement advocates future costs and effects consistently in value assessments to refine ICER applicability in cardiovascular guidelines, underscoring ongoing efforts to integrate and reduce reliance on outdated historical thresholds like the U.S. $50,000/QALY benchmark from 1990s decisions.

References

  1. [1]
    Incremental Cost-Effectiveness Ratio - ScienceDirect.com
    Incremental cost-effectiveness ratio (ICER) is defined as the difference in costs divided by the difference in effectiveness between two strategies, ...
  2. [2]
    Interpreting the Results of Cost-Effectiveness Studies - PMC - NIH
    Dec 16, 2008 · CE ratios are often reported as “incremental cost effectiveness ratios” (“iCERs” or “ICERs”), with the “i” emphasizing the notion that CE is not ...Fundamentals Of Health... · Key Principles In The... · Uncertainty
  3. [3]
    Cost utility analysis: health economic studies - GOV.UK
    Oct 13, 2020 · The ICER is calculated by taking the ratio between the incremental cost and the incremental QALY , which gives you the cost per additional QALY ...
  4. [4]
    Incremental Cost-Effectiveness Ratio (ICER) - York Health ...
    An ICER is calculated by dividing the difference in total costs (incremental cost) by the difference in the chosen measure of health outcome or effect ...
  5. [5]
    [PDF] Cost-Effectiveness Analysis (CEA)
    Incremental cost-effectiveness ratio (ICER). Once we have a measure of benefit we can calculate the ICER between alternatives. As we saw before: ICER = CA ...
  6. [6]
    Problems with interval estimates of the incremental cost ... - PubMed
    The problems are most prominent when the ICER is large and the true effectiveness difference is small relative to its standard error. A modification of the ...Missing: controversies | Show results with:controversies
  7. [7]
    Does Cost-Effectiveness Analysis Really Need to Abandon the ...
    Jan 8, 2020 · Dr Paulden has made the strong statement that it is time to abandon the incremental cost-effectiveness ratio (ICER) [ 1 ].
  8. [8]
    Cost-Effectiveness Analysis - HERC
    Here, we will define an incremental cost-effectiveness ratio (ICER), discuss how to evaluate statistical uncertainty, and present resources for finding the ...What is Cost-effectiveness... · Comparison of Multiple... · How Do I Evaluate the...
  9. [9]
    7 Assessing cost effectiveness | The guidelines manual - NICE
    Nov 30, 2012 · However, in general, interventions with an ICER of less than £20,000 per QALY gained are considered to be cost effective.
  10. [10]
    The NICE cost-effectiveness threshold: what it is and what that means
    The National Institute for Health and Clinical Excellence (NICE) has been using a cost-effectiveness threshold range between 20000 pound sterling and 30000 ...
  11. [11]
    [PDF] ICER 2019 Perspectives on Cost-Effectiveness Threshold Ranges
    ICER continues to use the threshold range from $100,000-$150,000 per QALY as the standard for its health-benefit price benchmarks for all assessments, but ...
  12. [12]
    Cost-effectiveness Plane - York Health Economics Consortium
    The plane is divided into four quadrants: the north-east quadrant commonly shows new interventions that offer greater health gains but at a higher cost.
  13. [13]
    Should NICE's cost-effectiveness thresholds change?
    Dec 13, 2024 · Over the years, some researchers have proposed that the threshold should be closer to around £15,000 per QALY gained. This was first suggested ...
  14. [14]
  15. [15]
    [PDF] Use of Cost-Effectiveness Analysis in Health Care - ISPOR
    • 1964: first CEA study published, by Klarman et al on renal dialysis and ... Health Economics and Policy 2019;17: 577-90).Missing: origins | Show results with:origins
  16. [16]
    [PDF] The Road to Cost-Effectiveness Analysis - Milbank Memorial Fund
    The first Brookings conference in 1964 commissioned a paper on some health problem or program (Klarman, 1965a). The. DeBakey Commission on Heart Disease, Cancer ...Missing: origins | Show results with:origins
  17. [17]
    Economic evaluation in healthcare. A brief history and future directions
    Economic evaluations started about 30 years ago as rather crude analyses, in which the value of improved health was measured in terms of increased labour ...
  18. [18]
    A History of Cost-Effectiveness | RAND
    Cost-effectiveness was not really an organized activity until after World War II. Historically, examples occurred in 11th-century China; 18th-century Bavaria; ...
  19. [19]
    NICE's cost effectiveness threshold - PMC - NIH
    NICE—which, since its inception in 1999, has adopted a cost effectiveness threshold range of £20 000 (€29 500; $40 000) to £30 000 per quality adjusted life ...
  20. [20]
    [PDF] NICE health technology evaluations: the manual
    Jan 31, 2022 · Below a most plausible ICER of £20,000 per QALY gained, or £100,000 per QALY gained for highly specialised technologies, the decision to ...
  21. [21]
    The Use of Incremental Cost-Effectiveness Ratio Thresholds in ...
    Health technology assessment (HTA) bodies in many countries have set an ICER threshold, above which an intervention is considered to be not cost-effective ...
  22. [22]
    [PDF] Valuing-a-Cure-Technical-Brief.pdf - ICER
    Aug 6, 2019 · Guidelines for the Economic Evaluation of Health Technologies: Canada. Canada: CADTH, 2006. ... The PBAC Guidelines explain in detail how to ...
  23. [23]
    The evolution of ICER's review process for new medical ... - NIH
    Since its inception in 2006, the Institute for Clinical and Economic Review (ICER) has rapidly gained influence on drug pricing and reimbursement decisions ...Abstract · Overview Of The 2018-2019... · Results Of Critical...
  24. [24]
    ICER Finalizes 2023 Updates to Value Assessment Framework
    Sep 25, 2023 · The process of updating ICER's value assessment framework included extensive benchmarking with health technology assessment (HTA) organizations ...
  25. [25]
    Cost–effectiveness analysis - Health system efficiency - NCBI - NIH
    This chapter discusses the potential use of CEA to achieve allocative efficiency (AE) at the health care organization (meso) and health system (macro) level.
  26. [26]
    Measuring Costs for Cost-Effectiveness Analysis
    To find the incremental cost-effectiveness ratio, the discount rate should be applied to both real costs and to outcomes measured as quality-adjusted life ...
  27. [27]
    NICE health technology evaluations: the manual | Guidance
    Incremental cost-effectiveness ratios (ICERs) reported must be the ratio of expected additional total cost to expected additional QALYs compared with ...
  28. [28]
    [PDF] A Guide to ICER's Methods for Health Technology Assessment
    Oct 27, 2020 · The threshold is updated annually to reflect changes in US medical and pharmaceutical spending as well as gross domestic product. Section 8 ...
  29. [29]
    Cost-Effectiveness, the QALY, and the evLY Gained - ICER
    To complement the use of the QALY, ICER's reports also include a calculation of the Equal Value of Life Years (evLY), which measures quality of life equally ...<|separator|>
  30. [30]
    Measuring the Benefits of Healthcare: DALYs and QALYs - NIH
    May 6, 2017 · In most of the analyses, QALYs gains were larger than DALYs avoided, which would lead to more favorable decisions regarding cost-effectiveness ...
  31. [31]
    Handling uncertainty in economic evaluations of healthcare ...
    The aim of this paper is to give an overview of the handling of uncertainty in economic evaluations of healthcare interventions.
  32. [32]
    Reflecting Uncertainty in Cost-Effectiveness Analysis
    The key objective of uncertainty analysis is to support better decision making. Uncertainty analysis can help inform the standard decision options of “accept” ...
  33. [33]
    Generating, Presenting, and Interpreting Cost-Effectiveness Results ...
    This tutorial aims to help make the best available methods for generating and presenting cost-effectiveness results with uncertainty common practice.
  34. [34]
    4.3 Probabilistic sensitivity analysis and value of information analysis
    Apr 20, 2023 · Probabilistic sensitivity analysis can help quantify parametric uncertainty in an economic model. Value of information analysis can then be employed to ...Probabilistic sensitivity analysis · Basic concept · Interpreting probabilistic...
  35. [35]
    Economic Evaluation Results Are Substantially Affected by ...
    This study could help to develop a guide for interpreting parameter correlation in probabilistic sensitivity analysis and provide a publicly available model for ...
  36. [36]
    Bringing in health technology assessment and cost‐effectiveness ...
    Cost‐effectiveness analysis compares the relative costs and outcome (effectiveness) of two or more alternative interventions for a defined indication or ...
  37. [37]
    How Does Cost-Effectiveness Analysis Inform Health Care Decisions?
    Like lower prices, a smaller ratio is more favorable because it implies that an intervention can produce an incremental health gain at a lower cost.
  38. [38]
    HTA67 Assessing Relationships Between the Canadian Agency for ...
    This analysis shows that CADTH revised ICERs were > 2x higher than sponsor reported ICERs, leading to significant price reduction recommendations.
  39. [39]
    The use of cost-effectiveness analysis for health benefit package ...
    Oct 9, 2023 · Incremental analysis is then used to prevent the adoption of inefficient new services or to support price negotiations on these. An example is ...
  40. [40]
    How Are Incremental Cost-Effectiveness, Contextual Considerations ...
    Apr 1, 2020 · This study reviews ICER assessments to explore the relationship between incremental cost-effectiveness, other benefits, and contextual factors on the value ...
  41. [41]
    HTA'd in the USA: A Comparison of ICER in the United States ... - NIH
    ICER uses a different approach for clinical review but performs cost-effectiveness analysis using methods similar to NICE. The key differences between NICE and ...
  42. [42]
    Incremental Cost-effectiveness Thresholds for Policy Decision-makers
    To aid decision-makers, an ICER threshold is sometimes used to determine which alternative option is cost-effective and included in hospital formularies. In the ...
  43. [43]
    Glossary
    ### Summary of Incremental Cost-Effectiveness Ratio (ICER) in NICE Decisions
  44. [44]
    Cost-effectiveness of cancer drugs: Comparative analysis of ... - NIH
    Nov 5, 2020 · ICER uses a cost-effectiveness threshold of $100,000 to $150,000 per QALY or below. In comparison, NICE utilizes a much lower threshold of £ ...
  45. [45]
    Economic evaluation of medicines - Australian Prescriber
    Apr 3, 2017 · In Australia, the PBAC does not have a specific threshold for funding new medicines, although a new drug with a cost less than $50 000 per QALY ...<|separator|>
  46. [46]
    Cost-effectiveness of surgical interventions in low-income and ... - NIH
    Oct 3, 2024 · The Incremental Cost-Effectiveness Ratio (ICER) is the standard metric for expressing the result of cost-effectiveness evaluation of a pair ...
  47. [47]
    The cost-effectiveness of vaccination against COVID-19 illness ...
    Feb 27, 2025 · The primary outcome is the incremental cost-effectiveness ratio (ICER), which is calculated by dividing the difference in costs by the ...
  48. [48]
    Use of the incremental cost-effectiveness ratio for decision-making ...
    Such controversial decisions appear to be a characteristic of Quality-Adjusted Life Year (QALY)-based Incremental Cost Effectiveness Ratio (ICER)-dominated ...Missing: "peer | Show results with:"peer
  49. [49]
    Systematic overview of cost–effectiveness thresholds in ten ...
    Oct 22, 2015 · To provide an overview of thresholds for incremental cost–effectiveness ratios (ICERs) representing willingness-to-pay (WTP) across multiple countries.
  50. [50]
    Thresholds for the cost–effectiveness of interventions - NIH
    Dec 15, 2014 · The incremental cost–effectiveness ratio, compared with doing nothing, is thus I$ 37 per 0.06 DALY averted – i.e. I$ 614 per DALY averted. At 10 ...
  51. [51]
    [PDF] WHITE PAPER - Office of Health Economics
    HTA and cost-effectiveness thresholds (CETs) were established to ensure public money is used to purchase interventions that provide the highest value (in terms ...
  52. [52]
    Investigation of Factors Considered by Health Technology ...
    Oct 27, 2020 · The present study reviewed four types of factors for the decision making across eight HTA organizations—economic evaluation types, clinical ...
  53. [53]
    [PDF] ICER Thresholds and League Tables
    Panel 135: HTA and Economic Analysis: Cost-Effectiveness. Threshold and ... • IQWiG/Germany: Efficiency frontier (EF) approach comparing. ICERs only ...
  54. [54]
    Country-Level Cost-Effectiveness Thresholds: Initial Estimates and ...
    The results of CEA are often expressed as an incremental cost-effectiveness ratio (ICER), the ratio of incremental costs to incremental health effects (∆costs/∆ ...
  55. [55]
    [PDF] the incremental cost-effectiveness ratio (icer) thresholds in ... - ISPOR
    In eight countries cost-effectiveness threshold is official (Bulgaria, Czechia,. Estonia, Hungary, Latvia, Lithuania, Poland and Slovakia), and four countries.
  56. [56]
    Variation in Health Technology Assessment and Reimbursement ...
    It has been suggested that differences in health technology assessment (HTA) processes among countries, particularly within Europe, have led to inequity in ...
  57. [57]
    Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence ...
    Jun 7, 2022 · In Australia, the Pharmaceutical Benefits Advisory Committee (PBAC) is believed to apply a threshold range of $45,000 to $60,000 per QALY [18], ...
  58. [58]
    On the Estimation of the Cost-Effectiveness Threshold
    The main argument of advocates of the opportunity cost approach is that information on society's valuation of improvements in health is irrelevant for threshold ...Comparative Effectiveness... · Demand-Side Empirical... · Wtp Surveys<|separator|>
  59. [59]
    [PDF] Does NICE have a cost effectiveness threshold and what other ...
    The results suggest a threshold somewhat higher than NICE's stated 'range of acceptable cost effectiveness' of £20,000 - £30,000 per QALY - although the exact ...
  60. [60]
    Determining the efficiency path to universal health coverage: cost ...
    ... gross domestic product (GDP) per capita. Most new threshold estimates in different countries show cost-effectiveness thresholds of less than 1 GDP per capita.
  61. [61]
    Strategies for Avoiding Neglect of Opportunity Costs by Decision ...
    Sep 1, 2021 · Here, we first confirm the relevance of empirical estimates of opportunity costs to informing the value of cost-effectiveness thresholds in ...Author Information · Ethics Declarations · Conflict Of Interest
  62. [62]
    Methods for the estimation of the National Institute for Health and ...
    There are no empirical estimates of the cost-effectiveness threshold used by the National Institute for Health and Care Excellence.Missing: supply side
  63. [63]
    Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence ...
    Jun 7, 2022 · In this paper, we consider the role of empirical estimates of supply-side thresholds in policy-making. Recent studies estimate the cost per unit of health ...<|separator|>
  64. [64]
    Cost-Effectiveness Threshold for Healthcare: Justification and ... - NIH
    Every public health expenditure, including the one that saves lives or extends life expectancy of particular persons (target population), bears a cost.
  65. [65]
    Estimating the range of incremental cost-effectiveness thresholds for ...
    Apr 14, 2022 · The study suggests a cost-effectiveness threshold range of 0.5–1.5 times GDP per capita, which is lower than the WHO's 1-3 times GDP per capita.
  66. [66]
    Country-Level Cost-Effectiveness Thresholds: Initial Estimates and ...
    Cost-effectiveness thresholds (CETs) are typically used to assess whether an intervention is worthwhile and should reflect health opportunity cost.
  67. [67]
    The cost-per-QALY threshold in England: Identifying structural ...
    This paper considers the uncertainty associated with estimating the opportunity cost of health system resources in the English National Health Service (NHS).
  68. [68]
    Why the government must urgently raise the NICE cost-effectiveness ...
    Oct 7, 2025 · This is the cost the NHS will pay to achieve one year of good health, currently £20,000 – £30,000 per Quality-Adjusted Life Year (QALY).Missing: selects | Show results with:selects
  69. [69]
    UK government mulls raising NICE cost-effectiveness threshold
    Oct 8, 2025 · The body currently deems a medicine worthy of NHS reimbursement if it costs less than £20,000 ($26,798) to £30,000 ($40,198) per quality- ...
  70. [70]
    UK set to raise NICE cost-effectiveness threshold amid US pressure ...
    Oct 10, 2025 · Currently set at £20,000–£30,000 per quality-adjusted life year (QALY), the threshold has remained static since 1999. As first reported by ...
  71. [71]
    Understanding the National Institute for Health and Care Excellence ...
    NICE indicates National Institute for Health and Care Excellence; QALY, quality-adjusted life-year. The new severity modifier replaces NICE's “end-of-life” (EoL) ...Missing: 1999 | Show results with:1999
  72. [72]
    Cost-effectiveness thresholds under political pressure: where are ...
    Oct 14, 2025 · Recent media reports have suggested that the UK government is preparing to increase the NICE cost-effectiveness threshold by 25%.Missing: criticisms | Show results with:criticisms
  73. [73]
    Affordability and Value in Decision Rules for Cost-Effectiveness
    We report results of a survey of researchers in which we assessed opinions about trade-offs between cost-effectiveness and affordability.
  74. [74]
    Incremental cost-effectiveness ratios (ICERs): the silence ... - PubMed
    To improve efficiency in resource allocation, decision-makers need information about the opportunity costs of programs. MeSH terms. Cost-Benefit Analysis / ...
  75. [75]
    Geographic Resource Allocation Based on Cost Effectiveness
    Feb 10, 2017 · The first decision selects the intervention option with the lowest ICER from all non-excluded options in all geo-units. This selection is the ...
  76. [76]
    The Influence of Cost‐Effectiveness and Other Factors on Nice ...
    Sep 23, 2014 · The objective of this study is to investigate the influence of cost-effectiveness and other factors on NICE decisions and whether NICE's decision-making has ...
  77. [77]
    What is ICER | Institute for Clinical & Economic Review
    ICER's goal is to bring more transparency to that conversation by 1) using evidence to determine the clinical benefit of health interventions, and 2) ensuring ...
  78. [78]
    HTA'd in the USA: A Comparison of ICER in the United States with ...
    Aug 28, 2020 · ICER is similar to NICE in its use of the incremental cost per QALY metric and in its methods for undertaking clinical and economic reviews.<|separator|>
  79. [79]
    Value Assessment Framework - ICER
    The ICER value framework describes the conceptual framework and set of associated methods that guide the development of ICER evidence reports.Potential Budget Impact... · Addendum For Assessment Of... · Icer 2019 Perspectives On...Missing: interpretation | Show results with:interpretation
  80. [80]
    Challenges in synthesising cost-effectiveness estimates
    Dec 9, 2020 · This paper aims to briefly summarise why conducting a meta-analysis of economic evaluation outcomes, focusing on incremental cost-effectiveness ratios, costs, ...Missing: controversies | Show results with:controversies
  81. [81]
    ICER, ISPOR AND QALYs: Tales of Imaginary Worlds - PMC
    The concern is that ICER gives the impression that there is a common and agreed utility metric to support QALY constructs and that there is an agreed standard ...
  82. [82]
    The Limits of Cost-Effectiveness Analysis | Circulation
    Jan 1, 2009 · The ICER should not be viewed only as a single number, as there is uncertainty to both the measure of the cost and the measure of effectiveness.
  83. [83]
    Hidden Costs: the ethics of cost-effectiveness analyses for health ...
    Cost-effectiveness thresholds are wrought with ethical conflicts. Thresholds define a dollar-per-QALY-gained or dollar-per-DALY-averted (i.e., ICER) cutoff of ...
  84. [84]
    Health Equity Considerations in Cost-Effectiveness Analysis
    Aug 20, 2024 · This umbrella review aimed to synthesize evidence on how equity concepts have been considered in modified types of CEAs.
  85. [85]
    Examining Equity Effects of Health Interventions in Cost ...
    Dec 3, 2020 · This systematic review aims to catalogue and describe published applications of equity-informative cost-effectiveness analysis (CEAs).
  86. [86]
    Innovations in cost-effectiveness analysis that advance equity can ...
    Feb 16, 2022 · Cost-effectiveness analysis (CEA) provides a useful framework to systematically assess and compare the expected costs and health benefits of two or more ...
  87. [87]
    [PDF] incorporating equity concerns into cost effectiveness analysis may ...
    For example, imagine an intervention which generates 5 additional QALYs at an additional cost of £125,000. The ICER of. £25,000 would be judged against an ...
  88. [88]
    Impacts of Cost-Effectiveness Assessments on Patient Access in ...
    Jan 10, 2025 · This analysis aims to assess the impact of the adoption of ICER cost-effectiveness determinations on patient access to UC medicines.<|separator|>
  89. [89]
    What is ICER & how does it impact the pharmaceutical industry?
    Sep 15, 2023 · ... patients, they can also negatively impact patient access to medicines. For example, an ICER assessment deeming a drug as a low value can ...
  90. [90]
    Patient Access Withers Under ICER's Influence
    Patients who are stable on advanced medicines may lose access to their treatment. ... ICER's controversial calculations, mean fewer treatment options.
  91. [91]
    How ICER's Flawed Budget Impact Threshold Can Harm Patient ...
    Jul 23, 2018 · According to the analysis, ICER estimates a range of patient access scenarios based on the calculation of a short-term budget impact threshold.
  92. [92]
    Analysis Finds Meaningful Impact on Pharmaceutical Innovation ...
    Feb 18, 2025 · For every 10% reduction in expected U.S. revenues, pharmaceutical innovation is expected to decline by up to 15%, finds a new Schaeffer ...
  93. [93]
    The Hidden Toll of Drug Price Controls: Fewer New Treatments and ...
    Jul 17, 2023 · When nations implement pharmaceutical price controls, they reduce pharmaceutical revenues, which then reduces investments in further R&D, limiting future ...
  94. [94]
    [PDF] Comments-on-Ultra-Rare-Disease-Framework-Adaptations ... - ICER
    ICER's limitation of costs to the health system undervalues the impact of orphan drugs, and will lead to decisions that shift costs to orphan disease patients, ...Missing: stifles | Show results with:stifles
  95. [95]
    The impact of rarity in NICE's health technology appraisals - NIH
    May 13, 2021 · Improved understanding of the challenges in drug development for orphan medicines and clearer guidance for decision makers on navigating ...<|separator|>
  96. [96]
    Achieving dynamic efficiency in pharmaceutical innovation ...
    Jan 16, 2024 · It has been argued that cost-effectiveness analysis of branded pharmaceuticals only considers static efficiency, neglects dynamic effects ...
  97. [97]
    ICER Misses…Again | National Pharmaceutical Council
    Dec 6, 2022 · ICER only considers data during one- or two-year periods, which ignores the effects of medicines on patients' well-being over a longer period of ...
  98. [98]
    Net benefit separation and the determination curve: a probabilistic ...
    The net monetary benefit aggregates information on differences in mean cost and clinical outcomes; the cost-effectiveness acceptability curve was then developed ...
  99. [99]
    Net Monetary Benefit (NMB) - Optimax Access
    ... cost-effectiveness ratios (ICERs). NMB is calculated using the following formula: NMB = (Incremental Benefit x Threshold) – Incremental Cost. Key aspects of ...
  100. [100]
    Net Benefits Calculations - TreeAge Pro
    In essence, the Net Benefits calculations combine cost, effectiveness and willingness-to-pay into a single measurement.
  101. [101]
    [PDF] Cost Effectiveness Analysis in Healthcare Decision-Making ...
    Stinnett and Mullahy (1998) proposed two (equivalent) alternatives called Net. Health Benefit (NHB) and Net Monetary Benefit (NMB). To define these, define a ...
  102. [102]
    [PDF] The cost-effectiveness of alternative vaccination strategies for ...
    Here, we estimate the health impact and cost associated with several alternative ... population's net monetary benefit (NMB) [46,47] ... ISPOR Health Economic ...<|separator|>
  103. [103]
    Glossary - NICE
    Net health benefit. The difference between the total expected quality-adjusted life years and the health expected to be forgone elsewhere (these are the total ...
  104. [104]
    Applying the net-benefit framework for assessing cost-effectiveness ...
    Jul 16, 2012 · ... efficiency of resource allocation. Traditionally, the use of cost ... (ICER) is significantly lower than the ICER computed. This is ...
  105. [105]
    [PDF] When Is Precision Public Health Cost Effective?
    ▫Incremental cost-effectiveness ratio (ICER), e.g., cost per QALY gained. ▫Some CEAs calculate net monetary benefit by multiplying QALYs by presumed ...
  106. [106]
    Use of Net Monetary Benefit Analysis to Comprehensively ...
    The NMB approach provides a useful framework that not only summarizes a therapy's overall value, but also clearly calculates the share of a treatment's value.
  107. [107]
    Multi-Criteria Decision Analysis for Assessment and Appraisal of ...
    Sep 30, 2016 · Multi-criteria decision analysis process consists of several steps: definition and structure of the problem; identification of a set of decision ...
  108. [108]
    [PDF] Health Economic Evaluations Incorporating Broader Perspectives
    May 11, 2024 · The 17 included studies are summarised in Table 2, with distributional cost-effectiveness analysis (DCEA) emerging as the most frequently used.
  109. [109]
    Beyond cost-effectiveness: A five-step framework for appraising the ...
    This manuscript presents a five-step framework that complements traditional health technology assessment (HTA) guidance documents that policymakers in Asia- ...
  110. [110]
    The Broader Opportunity Costs in the Broader Cost-Effectiveness ...
    This paper aims to develop a comprehensive framework that incorporates into the cost-effectiveness analysis framework some of its most advocated extensions.
  111. [111]
    Methods Update: Value Assessment Framework - ICER
    Jun 5, 2023 · ICER's 2023 update to our value assessment framework, which underpins our evidence reports on new drugs and other health care interventions.Missing: practices | Show results with:practices
  112. [112]
    NICE 2025 Appraisal Reforms: Impact on HST & STA Submissions
    Jul 7, 2025 · This process allows for a higher ICER threshold of £100,000, which may increase to £300,000 under exceptional circumstances.4 In December ...
  113. [113]
    Evolving Cost-Effectiveness Assessment for Cell and Gene Therapies
    Apr 13, 2025 · NICE now allows a lower 1.5% discount rate for both costs and health effects in certain circumstances, such as where treatments deliver ...
  114. [114]
    Guidelines for the Economic Evaluation of Health Technologies
    May 14, 2025 · In this case, the critical values would refer to parameter values that, for a given cost-effectiveness threshold, may change the decision.
  115. [115]
    2025 AHA/ACC Statement on Cost/Value Methodology in Clinical ...
    Sep 25, 2025 · The most widely used metric of cost-effectiveness is the incremental cost-effectiveness ratio or ICER, defined as the ratio of the net increase ...
  116. [116]
    A Preliminary Assessment of ICER's New HTA Methods ... - ISPOR
    In March 2023, ICER published a white paper with specific recommendations for addressing health equity concerns in health technology assessments (HTAs) and ...
  117. [117]
    ICER Thresholds in Cost-Utility Analysis: Assessing Conceptual ...
    Our research highlights a dissonance between CET and the needs of a decentralized US healthcare system, warranting consideration by academics and policymakers.Missing: ongoing | Show results with:ongoing
  118. [118]
    [PDF] ISPOR Response to ICER Framework Update – June 2023
    Jun 30, 2023 · We agree that ICER should use a range of alternative cost-effectiveness thresholds to illustrate the potential ... ICER reviews – external control ...
  119. [119]
    [PDF] ICER's Reference Case for Economic Evaluations: Elements and ...
    By non-intervention health care costs, ICER means all costs except those directly tied to administering the intervention or other modeled treatment options ( ...
  120. [120]
  121. [121]
  122. [122]
    [PDF] NICE decision-making ICER threshold analysis
    1 Central to this evaluation is the incremental cost-effectiveness ratio. (ICER), which represents the additional cost required to gain one additional QALY when ...
  123. [123]
    Estimating the range of incremental cost-effectiveness thresholds for ...
    Apr 14, 2022 · Our results suggest a CE threshold range of 0.5–1.5 times GDP per capita is appropriate but lower than the WHO-recommended range of 1–3 times.